To evaluate spectrum bias in stroke MRI analysis by excluding cases with uncertain acute ischemic lesions (AIL) and examining patient, imaging, and lesion factors associated with these cases. This single-center retrospective observational study included adults with brain MRIs for suspected stroke between January 2020 and April 2022. Diagnostic uncertain AIL were identified through reader disagreement or low certainty grading by a radiology resident, a neuroradiologist, and the original radiology report consisting of various neuroradiologists. A commercially available deep learning tool analyzing brain MRIs for AIL was evaluated to assess the impact of excluding uncertain cases on diagnostic odds ratios. Patient-related, MRI acquisition-related, and lesion-related factors were analyzed using the Wilcoxon rank sum test, χ2 test, and multiple logistic regression. The study was approved by the National Committee on Health Research Ethics. In 989 patients (median age 73 (IQR: 59-80), 53% female), certain AIL were found in 374 (38%), uncertain AIL in 63 (6%), and no AIL in 552 (56%). Excluding uncertain cases led to a four-fold increase in the diagnostic odds ratio (from 68 to 278), while a simulated case-control design resulted in a six-fold increase compared to the full disease spectrum (from 68 to 431). Independent factors associated with uncertain AIL were MRI artifacts, smaller lesion size, older lesion age, and infratentorial location. Excluding uncertain cases leads to a four-fold overestimation of the diagnostic odds ratio. MRI artifacts, smaller lesion size, infratentorial location, and older lesion age are associated with uncertain AIL and should be accounted for in validation studies.

BackgroundIn glioblastoma (GBM), promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) is associated with beneficial chemotherapy but has not been accurately evaluated based on radiological and pathological sections. To develop and validate an MRI and pathology image-based deep learning radiopathomics model for predicting MGMT promoter methylation in patients with GBM. MethodsA retrospective collection of pathologically confirmed isocitrate dehydrogenase (IDH) wild-type GBM patients (n=207) from three centers was performed, all of whom underwent MRI scanning within 2 weeks prior to surgery. The pre-trained ResNet50 was used as the feature extractor. Features of 1024 dimensions were extracted from MRI and pathological images, respectively, and the features were screened for modeling. Then feature fusion was performed by calculating the normalized multimode MRI fusion features and pathological features, and prediction models of MGMT based on deep learning radiomics, pathomics, and radiopathomics (DLRM, DLPM, DLRPM) were constructed and applied to internal and external validation cohorts. ResultsIn the training, internal and external validation cohorts, the DLRPM further improved the predictive performance, with a significantly better predictive performance than the DLRM and DLPM, with AUCs of 0.920 (95% CI 0.870-0.968), 0.854 (95% CI 0.702-1), and 0.840 (95% CI 0.625-1). ConclusionWe developed and validated cross-scale radiology and pathology models for predicting MGMT methylation status, with DLRPM predicting the best performance, and this cross-scale approach paves the way for further research and clinical applications in the future.

Alzheimers Disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. In 2024, in the US alone, it affected approximately 1 in 9 people aged 65 and older, equivalent to 6.9 million individuals. Early detection and accurate AD diagnosis are crucial for improving patient outcomes. Magnetic resonance imaging (MRI) has emerged as a valuable tool for examining brain structure and identifying potential AD biomarkers. This study performs predictive analyses by employing machine learning techniques to identify key brain regions associated with AD using numerical data derived from anatomical MRI scans, going beyond standard statistical methods. Using the Random Forest Algorithm, we achieved 92.87% accuracy in detecting AD from Mild Cognitive Impairment and Cognitive Normals. Subgroup analyses across nine sex- and age-based cohorts (69-76 years, 77-84 years, and unified 69-84 years) revealed the hippocampus, amygdala, and entorhinal cortex as consistent top-rank predictors. These regions showed distinct volume reductions across age and sex groups, reflecting distinct age- and sex-related neuroanatomical patterns. For instance, younger males and females (aged 69-76) exhibited volume decreases in the right hippocampus, suggesting its importance in the early stages of AD. Older males (77-84) showed substantial volume decreases in the left inferior temporal cortex. Additionally, the left middle temporal cortex showed decreased volume in females, suggesting a potential female-specific influence, while the right entorhinal cortex may have a male-specific impact. These age-specific sex differences could inform clinical research and treatment strategies, aiding in identifying neuroanatomical markers and therapeutic targets for future clinical interventions.

Timely intervention for Alzheimers disease (AD) requires early detection. The development of immunotherapies targeting amyloid-beta and tau underscores the need for accessible, time-efficient biomarkers for early diagnosis. Here, we directly applied our previously developed MRI-based deep learning model for AD to the large Chinese SILCODE cohort (722 participants, 1,105 brain MRI scans). The model -- initially trained on North American data -- demonstrated robust cross-ethnic generalization, without any retraining or fine-tuning, achieving an AUC of 91.3% in AD classification with a sensitivity of 95.2%. It successfully identified 86.7% of individuals at risk of AD progression more than 5 years in advance. Individuals identified as high-risk exhibited significantly shorter median progression times. By integrating an interpretable deep learning brain risk map approach, we identified AD brain subtypes, including an MCI subtype associated with rapid cognitive decline. The models risk scores showed significant correlations with cognitive measures and plasma biomarkers, such as tau proteins and neurofilament light chain (NfL). These findings underscore the exceptional generalizability and clinical utility of MRI-based deep learning models, especially in large and diverse populations, offering valuable tools for early therapeutic intervention. The model has been made open-source and deployed to a free online website for AD risk prediction, to assist in early screening and intervention.

To develop an early budget impact analysis of and inform future research on the national adoption of a commercially available AI application to support clinicians reviewing radiographs for suspected fractures across NHS emergency departments in England. A decision tree framework was coded to assess a change in outcomes for suspected fractures in adults when AI fracture detection was integrated into clinical workflow over a 1-year time horizon. Standard of care was the comparator scenario and the ground truth reference cases were characterised by radiology report findings. The effect of AI on assisting ED clinicians when detecting fractures was sourced from US literature. Data on resource use conditioned on the correct identification of a fracture in the ED was extracted from a London NHS trust. Sensitivity analysis was conducted to account for the influence of parameter uncertainty on results. In one year, an estimated 658,564 radiographs were performed in emergency departments across England for suspected wrist, ankle or hip fractures. The number of patients returning to the ED with a missed fracture was reduced by 21,674 cases and a reduction of 20, 916 unnecessary referrals to fracture clinics. The cost of current practice was estimated at £66,646,542 and £63,012,150 with the integration of AI. Overall, generating a return on investment of £3,634,392 to the NHS. The adoption of AI in EDs across England has the potential to generate cost savings. However, additional evidence on radiograph review accuracy and subsequent resource use is required to further demonstrate this.

Timely intervention and improved prognosis for breast cancer patients rely on early metastasis risk detection and accurate treatment predictions. This study introduces an advanced multimodal MRI and AI-driven 3D deep learning model, termed the 3D-MMR-model, designed to predict recurrence risk in non-metastatic breast cancer patients. We conducted a multicenter study involving 1199 non-metastatic breast cancer patients from four institutions in China, with comprehensive MRI and clinical data retrospectively collected. Our model employed multimodal-data fusion, utilizing contrast-enhanced T1-weighted imaging (T1 + C) and T2-weighted imaging (T2WI) volumes, processed through a modified 3D-UNet for tumor segmentation and a DenseNet121-based architecture for disease-free survival (DFS) prediction. Additionally, we performed RNA-seq analysis to delve further into the relationship between concentrated hotspots within the tumor region and the tumor microenvironment. The 3D-MR-model demonstrated superior predictive performance, with time-dependent ROC analysis yielding AUC values of 0.90, 0.89, and 0.88 for 2-, 3-, and 4-year DFS predictions, respectively, in the training cohort. External validation cohorts corroborated these findings, highlighting the model's robustness across diverse clinical settings. Integration of clinicopathological features further enhanced the model's accuracy, with a multimodal approach significantly improving risk stratification and decision-making in clinical practice. Visualization techniques provided insights into the decision-making process, correlating predictions with tumor microenvironment characteristics. In summary, the 3D-MMR-model represents a significant advancement in breast cancer prognosis, combining cutting-edge AI technology with multimodal imaging to deliver precise and clinically relevant predictions of recurrence risk. This innovative approach holds promise for enhancing patient outcomes and guiding individualized treatment plans in breast cancer care.

Craniopharyngiomas (CPs) are rare, benign brain tumors originating from Rathke's pouch remnants, typically located in the sellar/parasellar region. Accurate differentiation is crucial due to varying prognoses, with ACPs having higher recurrence and worse outcomes. MRI struggles with overlapping features, complicating diagnosis. this study evaluates the role of Artificial Intelligence (AI) in diagnosing, segmenting, and classifying CPs, emphasizing its potential to improve clinical decision-making, particularly for radiologists and neurosurgeons. This systematic review and meta-analysis assess AI applications in diagnosing, segmenting, and classifying on CPs patients. a comprehensive search was conducted across PubMed, Scopus, Embase and Web of Science for studies employing AI models in patients with CP. Performance metrics such as sensitivity, specificity, accuracy, and area under the curve (AUC) were extracted and synthesized. Eleven studies involving 1916 patients were included in the analysis. The pooled results revealed a sensitivity of 0.740 (95% CI: 0.673-0.808), specificity of 0.813 (95% CI: 0.729-0.898), and accuracy of 0.746 (95% CI: 0.679-0.813). The area under the curve (AUC) for diagnosis was 0.793 (95% CI: 0.719-0.866), and for classification, it was 0.899 (95% CI: 0.846-0.951). The sensitivity for segmentation was found to be 0.755 (95% CI: 0.704-0.805). AI-based models show strong potential in enhancing the diagnostic accuracy and clinical decision-making process for CPs. These findings support the use of AI tools for more reliable preoperative assessment, leading to better treatment planning and patient outcomes. Further research with larger datasets is needed to optimize and validate AI applications in clinical practice.

Coronary artery disease (CAD) is highly prevalent among pilots due to the nature of their lifestyle, and occupational stresses. CAD is one the most common conditions affecting pilots' medical certification and is frequently nondisclosed by pilots fearing the loss of their certification. Traditional screening methods, such as resting electrocardiograms (EKGs) and functional stress tests, have limitations, especially in detecting non-obstructive CAD. Recent advances in cardiac imaging are challenging the current paradigms of CAD screening and risk assessment protocols, offering tools uniquely suited to address the occupational health challenges faced by pilots. Coronary artery calcium scoring (CACS) has proven valuable in refining risk stratification in asymptomatic individuals. Coronary computed tomography angiography (CCTA), is being increasingly adopted as a superior tool for ruling out CAD in symptomatic individuals, assessing plaque burden as well as morphologically identifying vulnerable plaque. CT-derived fractional flow reserve (CT-FFR) adds a physiologic component to the anatomical prowess of CCTA. Cardiac magnetic resonance imaging (CMR) is now used as a prognosticating tool following a coronary event as well as a stress testing modality. Investigational technologies like pericoronary fat attenuation and artificial intelligence (AI)-enabled plaque quantification hold the promise of enhancing diagnostic accuracy and risk stratification. This review highlights the interplay between occupational demands, regulatory considerations, and the limitations of the traditional modalities for pilot CAD screening and surveillance. We also discuss the potential role of the recent advances in cardiac imaging in optimizing pilot health and flight safety.

Artificial intelligence (AI) is now transforming medical imaging, with extensive ramifications for nearly every aspect of diagnostic imaging, including computed tomography (CT). This current work aims to review, evaluate, and summarise the role of AI in radiation dose optimisation across three fundamental domains in CT: patient positioning, scan range determination, and image reconstruction. A comprehensive scoping review of the literature was performed. Electronic databases including Scopus, Ovid, EBSCOhost and PubMed were searched between January 2018 and December 2024. Relevant articles were identified from their titles had their abstracts evaluated, and those deemed relevant had their full text reviewed. Extracted data from selected studies included the application of AI, radiation dose, anatomical part, and any relevant evaluation metrics based on the CT parameter in which AI is applied. 90 articles met the selection criteria. Included studies evaluated the performance of AI for dose optimisation through patient positioning, scan range determination, and reconstruction across various CT scans, including the abdomen, chest, head, neck, and pelvis, as well as CT angiography. A concise overview of the present state of AI in these three domains, emphasising benefits, limitations, and impact on the transformation of dose reduction in CT scanning, is provided. AI methods can help minimise positioning offsets and over-scanning caused by manual errors and helped to overcome the limitation associated with low-dose CT settings through deep learning image reconstruction algorithms. Further clinical integration of AI will continue to allow for improvements in optimising CT scan protocols and radiation dose. This review underscores the significance of AI in optimizing radiation doses in CT imaging, focusing on three key areas: patient positioning, scan range determination, and image reconstruction.

Cardiovascular diseases are the number one cause of death globally, making cardiac magnetic resonance image segmentation a popular research topic. Existing schemas relying on manual user interaction or semi-automatic segmentation are infeasible when dealing thousands of cardiac MRI studies. Thus, we proposed a full automatic and robust algorithm for large-scale cardiac MRI segmentation by combining the advantages of deep learning localization and 3D-ASM restriction. The proposed method comprises several key techniques: 1) a hybrid network integrating CNNs and Transformer as a encoder with the EFG (Edge feature guidance) module (named as CTr-HNs) to localize the target regions of the cardiac on MRI images, 2) initial shape acquisition by alignment of coarse segmentation contours to the initial surface model of 3D-ASM, 3) refinement of the initial shape to cover all slices of MRI in the short axis by complex transformation. The datasets used are from the UK BioBank and the CAP (Cardiac Atlas Project). In cardiac coarse segmentation experiments on MR images, Dice coefficients (Dice), mean contour distances (MCD), and mean Hausdorff distances (HD95) are used to evaluate segmentation performance. In SPASM experiments, Point-to-surface (P2S) distances, Dice score are compared between automatic results and ground truth. The CTr-HNs from our proposed method achieves Dice coefficients (Dice), mean contour distances (MCD), and mean Hausdorff distances (HD95) of 0.95, 0.10 and 1.54 for the LV segmentation respectively, 0.88, 0.13 and 1.94 for the LV myocardium segmentation, and 0.91, 0.24 and 3.25 for the RV segmentation. The overall P2S errors from our proposed schema is 1.45 mm. For endocardium and epicardium, the Dice scores are 0.87 and 0.91 respectively. Our experimental results show that the proposed schema can automatically analyze large-scale quantification from population cardiac images with robustness and accuracy.